Product Description
Mechanisms of Action: NCCT Inhibitor,CA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Bangladesh | Brazil | Chile | Colombia | Dominican Republic | India | Ireland | Malaysia | Mexico | New Zealand | Pakistan | Peru | South Africa | Taiwan | Tunisia | Turkey | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Adicet Bio
Company Location: BOSTON MA 02116
Company CEO: Chen Schor
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: New Zealand
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Influenza, Human|Respiratory Tract Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2006-7041-83/hah | P2 |
Not yet recruiting |
Respiratory Tract Infections|Influenza, Human |
2018-05-25 |